Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GlaxoSmithKline PLC
As clinical trials of potential coronavirus vaccines continue, the UK government has drawn up a list of those who should be first in line for vaccination, although it cautions that many unknowns remain in areas such as efficacy, dosing schedules and duration of protection.
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
The latest drug development news and highlights from our US FDA Performance Tracker.
Improving gender balance in top pharma is a slow process, but not a gradual one. Management shake-ups often implemented by newly appointed CEOs could help.
With EpiPen injector patent-protected and patients accustomed to its use, finding a substitutable generic device may prove difficult.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.